{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:10:23Z","timestamp":1794028223791,"version":"4.8.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study evaluated short- and long-term efficacy and safety of the second-generation somatostatin receptor ligand pasireotide alone or in combination with dopamine agonist cabergoline in patients with Cushing\u2019s disease (CD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Study design<\/jats:title><jats:p>This is an open-label, multicenter, non-comparative, Phase II study comprising 35-week core phase and an optional extension phase. All patients started with pasireotide, and cabergoline was added if cortisol remained elevated. Eligible patients had active CD, with or without prior surgery, were pasireotide na\u00efve at screening or had discontinued pasireotide for reasons other than safety. Primary endpoint was proportion of patients with a mean urinary free cortisol (mUFC) level not exceeding the upper limit of normal (ULN) at week 35 with missing data imputed using last available post-baseline assessments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 68 patients enrolled, 26 (38.2%) received pasireotide monotherapy and 42 (61.8%) received pasireotide plus cabergoline during the core phase. Thirty-four patients (50.0%; 95% CI 37.6\u201362.4) achieved the primary endpoint, of whom 17 (50.0%) received pasireotide monotherapy and 17 (50.0%) received combination therapy. Proportion of patients with mUFC control remained stable during the extension phase up to week 99. Treatment with either mono or combination therapy provided sustained improvements in clinical symptoms of hypercortisolism up to week 99. Hyperglycemia and nausea (51.5% each), diarrhea (44.1%) and cholelithiasis (33.8%) were the most frequent adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Addition of cabergoline in patients with persistently elevated mUFC on maximum tolerated doses of pasireotide is an effective and well-tolerated long-term strategy for enhancing control of hypercortisolism in some CD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:ext-link>https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01915303<\/jats:ext-link>, identifier NCT01915303.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1165681","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T12:46:18Z","timestamp":1696855578000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing\u2019s disease"],"prefix":"10.3389","volume":"14","author":[{"given":"Richard A.","family":"Feelders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fleseriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar","family":"Kadioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Bex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyanira","family":"Gonz\u00e1lez-Devia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar Luiz","family":"Boguszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek Gogas","family":"Yavuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Patino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto M.","family":"Pedroncelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Maamari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arghya","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly M. K.","family":"Biller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(14)61375-1","article-title":"Cushing\u2019s syndrome","volume":"386","author":"Lacroix","year":"2015","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(18)30155-4","article-title":"Advances in the medical treatment of Cushing\u2019s syndrome","volume":"7","author":"Feelders","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2016.118","article-title":"Mortality in cushing disease","volume":"12","author":"Newell-Price","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.mce.2007.09.006","article-title":"Pasireotide (SOM230): Development, mechanism of action and potential applications","volume":"286","author":"Schmid","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month Phase 3 study of pasireotide in Cushing\u2019s disease","volume":"366","author":"Colao","year":"2012","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/s2213-8587(17)30326-1","article-title":"Efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a 12 month clinical trial","volume":"6","author":"Lacroix","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14081","article-title":"Long-term efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: A Phase III extension study","volume":"91","author":"Fleseriu","year":"2019","journal-title":"Clin Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-017-1316-3","article-title":"Long-term treatment of Cushing\u2019s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial","volume":"57","author":"Petersenn","year":"2017","journal-title":"Endocrine"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00436","article-title":"Safety and efficacy of subcutaneous pasireotide in patients with Cushing\u2019s disease: results from an open-label, multicenter, single-arm, multinational, expanded-access study","volume":"10","author":"Fleseriu","year":"2019","journal-title":"Original Res Front Endocrinol (Lausanne)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1533","article-title":"The medical treatment of Cushing\u2019s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery","volume":"94","author":"Pivonello","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1530\/eje-10-0382","article-title":"Cabergoline monotherapy in the long-term treatment of Cushing\u2019s disease","volume":"163","author":"Godbout","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1530\/eje-16-0662","article-title":"Cabergoline for Cushing\u2019s disease: a large retrospective multicenter study","volume":"176","author":"Ferriere","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-018-0936-7","article-title":"Effect of cabergoline monotherapy in Cushing\u2019s disease: an individual participant data meta-analysis","volume":"41","author":"Palui","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"B15","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s40618-021-01723-0","article-title":"Correction to: Palui R, Sahoo J, Kamalanathan S, Kar SS, Selvarajan S, Durgia H. Effect of cabergoline monotherapy in Cushing\u2019 disease: an individual participant data meta-analysis. J Endocrinol Invest. 2018; 41(12):1445-1455. Doi: 10.1007\/s40618-018-0936-7","volume":"45","author":"Palui","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"B16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1530\/eje-15-0807","article-title":"Limited value of cabergoline in Cushing\u2019s disease: a prospective study of a 6-week treatment in 20 patients","volume":"174","author":"Burman","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02348","article-title":"Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours","volume":"156","author":"Colao","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1000094","article-title":"Pasireotide alone or with cabergoline and ketoconazole in Cushing\u2019s disease","volume":"362","author":"Feelders","year":"2010","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1530\/eje-07-0762","article-title":"Evaluation of health-related quality of life in patients with Cushing\u2019s syndrome with a new questionnaire","volume":"158","author":"Webb","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-013-0475-3","article-title":"Combination therapy for Cushing\u2019s disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole?","volume":"17","author":"Barbot","year":"2014","journal-title":"Pituitary"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-009-0209-8","article-title":"Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease","volume":"13","author":"Vilar","year":"2010","journal-title":"Pituitary"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0536","article-title":"Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome","volume":"96","author":"Kamenick\u00fd","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1008","article-title":"Treatment of pituitary-dependent Cushing\u2019s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, Phase II trial","volume":"94","author":"Boscaro","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/science.288.5463.154","article-title":"Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity","volume":"288","author":"Rocheville","year":"2000","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2007.07.007","article-title":"Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis","volume":"19","author":"Baragli","year":"2007","journal-title":"Cell Signal"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00648","article-title":"Medical treatment of Cushing's disease: an overview of the current and recent clinical trials","volume":"11","author":"Pivonello","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2020.1802243","article-title":"Management of patients with persistent or recurrent Cushing\u2019s disease after initial pituitary surgery","volume":"15","author":"Capatina","year":"2020","journal-title":"Expert Rev Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1530\/EJE-19-0762","article-title":"Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study","volume":"182","author":"Colao","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0206-1","article-title":"Cabergoline treatment in acromegaly: pros","volume":"46","author":"Marazuela","year":"2014","journal-title":"Endocrine"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/endo-meetings.2011.PART4.P5.P3-535","article-title":"P3-535, Pasireotide treatment in cushing disease: effects on the IGF-I system","volume":"32","author":"Varewijck","year":"2011","journal-title":"Endocr Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2013.5","article-title":"Glucocorticoids and the regulation of growth hormone secretion","volume":"9","author":"Mazziotti","year":"2013","journal-title":"Nat Rev Endocrinol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/coc.0000000000000505","article-title":"Cabergoline in the management of residual nonfunctioning pituitary adenoma: a single-center, open-label, 2-year randomized clinical trial","volume":"42","author":"Batista","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-019-01021-2","article-title":"Pasireotide treatment significantly reduces tumor volume in patients with Cushing\u2019s disease: results from a Phase 3 study","volume":"23","author":"Lacroix","year":"2020","journal-title":"Pituitary"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0557-2","article-title":"The treatment with pasireotide in Cushing\u2019s disease: effects of long-term treatment on tumor mass in the experience of a single center","volume":"50","author":"Simeoli","year":"2015","journal-title":"Endocrine"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-011-0309-0","article-title":"Macrocorticotropinoma shrinkage and control of hypercortisolism under long-term cabergoline therapy: case report","volume":"15","author":"Manavela","year":"2012","journal-title":"Pituitary"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01246-0","article-title":"Long-acting pasireotide improves clinical signs and quality of life in Cushing\u2019s disease: results from a phase III study","volume":"43","author":"Lacroix","year":"2020","journal-title":"J Endocrinol Invest."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.579606","article-title":"Depression and impulsivity self-assessment tools to identify dopamine agonist side effects in patients with pituitary adenomas","volume":"11","author":"Hinojosa-Amaya","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","article-title":"Dopamine agonists and impulse control disorders: a complex association","volume":"41","author":"Grall-Bronnec","year":"2018","journal-title":"Drug Saf."}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1165681\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T12:46:22Z","timestamp":1696855582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1165681\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":38,"alternative-id":["10.3389\/fendo.2023.1165681"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1165681","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,9]]},"article-number":"1165681"}}